BRAF and non-small cell lung carcinoma: Similar to the National Cancer Institute exceptional response initiative, our study started from a clinical retrospective observation: two patients with EGFR wild-type NSCLC who responded to erlotinib.19 Then, we established BRAF class 3–mutated NSCLC cell lines and confirmed their sensitivity to EGFR-TKIs.